Special Issue Article
Calciphylaxis: Current Management and Emerging Therapies
- *Corresponding Author:
- Vassilios Liakopoulos
Assistant Professor of Nephrology, Division of Nephrology
1st Department of Internal Medicine, Medical School
Aristotle University of Thessaloniki, AHEPA Hospital
1 S. Kyriakidi street, 54634, Thessaloniki, Greece
E-mail: [email protected]
Received Date: November 15, 2011; Accepted Date: January 04, 2012; Published Date: January 06, 2012
Citation: Eleftheriadis T, Leivaditis K, Antoniadi G, Liakopoulos V (2012) Calciphylaxis: Current Management and Emerging Therapies. J Nephrol Therapeutic S1:001. doi: 10.4172/2161-0959.S1-001
Copyright: © 2012 Eleftheriadis T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Calciphylaxis or calcific uremic arteriolopathy is a relatively uncommon condition with poor prognosis. Although it is predominantly observed in patients with end stage renal disease, a few cases of patients without kidney failure have been reported. Calciphylaxis is characterized by calcification of the arteriolar intima media and eventually by vascular thrombosis, tissue ischemia and painful skin necrosis. Septicemia is the main cause of death. According to published literature concerning the pathology of calciphylaxis, prevention and treatment are principally based on interventions in calcium and phosphorus metabolism. Although novel therapies have emerged, due to the rarity of this condition, there is no sufficient data in favor of a certain treatment.